Mar 23, 2026
Geneva/Labège, 23 March 2026. The French biotech company Antabio and the GARDP Foundation (known as GARDP) today announced a joint effort to accelerate crucial early-stage antibiotic discovery, responding to a steep rise in drug-resistant infections...
Sep 3, 2024
Labège, France, September 3rd, 2024. Antabio, a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens, with a particular focus on life-threatening respiratory infections, today announced...
Dec 12, 2023
Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion of Phase 2 trials. Labège, France, 12 December 2023. Antabio SAS, a...
May 25, 2023
Labège, France, May 25th 2023. Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug resistant bacterial infections, announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310. MEM-ANT3310 is a...
Jan 6, 2022
Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million out of a total estimated budget of €17 million. ARPEGE...
Mar 16, 2021
Une aide de 886 020 euros au titre du Contrat Innovation Région est attribuée pour le développement de ANT3310-MEM, un produit destiné à lutter contre les infections respiratoires acquises à l’hôpital. Labège, France, 16 Mars, 2021. Antabio SAS, société...
